50 closest statements
by meaning · ranked by similarity · 100 per pageMeaning search returns the 50 nearest statements, then applies your filters.
“Our mission is to maximize the value of ganaxolone as a best-in-class therapy for rare seizure and neurological disorders through development of multiple formulations for oral and IV administration.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-0589% match
“Our mission is to develop transformative medicines to improve the lives of patients with central nervous system (CNS) disorders, such as Tuberous Sclerosis Complex (TSC)-related epilepsy and other diseases associated with dysregulation or overexpression of filamin A. Our science is based on modulating the activity of a critical protein in the brain for patients with certain CNS disorders, such as TSC.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1266% match
“Our mission is to create disease-modifying neurogenetic medicines by identifying validated targets, advancing multiple therapeutic modalities, and delivering them to the right areas within the central nervous system.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-03-1165% match
“Our mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients suffering from brain diseases.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-0765% match
“Our mission is to identify, develop, and, directly or through collaborations, bring to market novel products for the treatment of rare and ultra-rare diseases or conditions.”In use 2019 – now·1 sighting·SEC Form 10-K, filed 2019-03-1464% match
“Our mission is to improve patient outcomes in the areas of neurodegenerative and oncological diseases by developing safe and effective cellular therapies that leverage the power of a patient’s immune system.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-10-0864% match
“The Company's mission is to identify, develop and commercialize specialty pharmaceutical products that exceed the expectations of patients, customers and stockholders with a high-performance culture and preeminent ethical standards.”In use 2018 – now·1 sighting·SEC Form 10-K, filed 2018-03-0864% match
“Our mission is to build a leading, fully integrated global rare disease company using our patient-centric approach to identify and develop life-transforming medicines for the treatment of severe rare diseases.”In use 2023 – now·1 sighting·SEC Form 20-F, filed 2023-04-1964% match
“Our mission is to develop drugs that optimize health outcomes and improve patients’ quality of life.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-3164% match
“Our mission is to develop first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy, or DMD, and other rare disorders.”In use 2020 – now·1 sighting·SEC Form 10-K, filed 2020-03-2764% match
“Our mission is to discover and develop effective biologic treatments for people with life-threatening conditions and to evolve Inhibrx into a commercial-stage biopharmaceutical company with a differentiated and sustainable product portfolio by focusing on the following:.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-02-2864% match
“Our mission is to develop a variety of first-in-class and best-in-class product candidates customized in an effort to optimize safety, efficacy, and convenience that we believe may offer improved patient experiences.”In use 2010 – now·1 sighting·SEC Form 10-K, filed 2010-03-1564% match
“Our mission is to become a global leader in the treatment of rare diseases through commercializing, developing and acquiring novel rare disease products.”In use 2021 – now·1 sighting·SEC Form 424B4, filed 2021-01-1464% match
“Our mission is to be the global leader and pioneer of this new treatment paradigm, integrating recombinant technology, gene therapy and cell therapy to address the challenges of targeting and delivering effective therapies, including to the brain for cancer and other central nervous system (“CNS”) indications.”In use 2026 – now·1 sighting·SEC Form S-1, filed 2026-08-2864% match
“Our mission is to be a leader in developing and manufacturing pharmaceutical products in unique and convenient oral delivery formats using science and innovation to improve people's lives.”In use 2009 – now·1 sighting·SEC Form 10-K, filed 2009-04-2464% match
“Our mission is to develop novel proprietary mebufotenin therapies to induce ultra-rapid and durable remissions in patients with psychiatric and neurological disorders.”In use 2026 – now·1 sighting·SEC Form 20-F, filed 2026-03-0564% match
“Our mission is to develop, register and commercialize safe and effective drugs, with novel mechanisms of action, to meet the major unmet medical needs of patients on a global basis.”In use 2012 – now·1 sighting·SEC Form 10-K, filed 2012-03-1564% match
“Our mission is to design and deliver next generation immunotherapies for neurodegenerative and neuroinflammatory diseases.”In use 2026 – now·1 sighting·SEC Form 20-F, filed 2026-05-0163% match
“Our mission is to develop and commercialize first-in-class medicines based on novel targets to improve patients’ lives.”In use 2022 – now·1 sighting·SEC Form 20-F, filed 2022-03-2463% match
“Our mission is to discover and develop best- and first-in-class medicines for a broad range of difficult-to-treat diseases in collaboration with our partners.”In use 2026 – now·1 sighting·SEC Form 20-F, filed 2026-04-0863% match
“Our mission is to develop therapeutic drugs designed to treat neurodegenerative diseases, currently focusing on Parkinsonian and other movement disorders.”In use 2026 – now·1 sighting·SEC Form 20-F, filed 2026-08-2863% match
“Our mission is to be a global leader in generics, innovative medicines and biopharmaceuticals, improving the lives of patients.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-02-1263% match
“Our mission is to become a leading global, fully integrated biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class therapies to address global unmet medical needs primarily in hematological malignancies.”In use 2025 – now·1 sighting·SEC Form 424B4, filed 2025-01-2463% match
“Our mission is to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte, or TIL, cell therapies for patients with solid tumor cancers.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2463% match
“Our mission is to develop therapeutic products with the potential to address high unmet medical needs by identifying promising clinical-stage candidates and advancing their development to create products that will improve patients’ lives.”In use 2026 – now·1 sighting·SEC Form S-1, filed 2026-08-2163% match
“Our mission is to create safe and effective oral medicines to engage novel targets in therapeutic areas of unmet medical need where current treatments have limited efficacy or safety and tolerability concerns.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-2162% match
“Our mission is to provide therapeutic relief to those suffering from debilitating rare diseases that have limited or no treatment options to help them live their best possible lives and achieve their full potential.”In use 2024 – now·1 sighting·SEC Form 20-F, filed 2024-04-3062% match
“Our mission is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of our patients.”In use 2019 – now·1 sighting·SEC Form 10-K, filed 2019-03-0762% match
“Our mission is to discover and develop novel therapeutics to improve the lives of patients living with debilitating CNS disorders.”In use 2025 – now·1 sighting·SEC Form S-1/A, filed 2025-10-0662% match
“Our mission is to discover, develop and ultimately deliver medicines that are transformational for patients.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-2862% match
“Our mission is to develop and commercialize novel and best-in-class therapeutics to address unmet medical needs in the emerging otology market.”In use 2015 – now·1 sighting·SEC Form 10-K, filed 2015-03-1862% match
“Our mission is to commercialize innovative drug candidates with novel mechanisms of action as well as intellectual property generated from our research activities for neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease.”In use 2018 – now·1 sighting·SEC Form 10-K, filed 2018-07-1662% match
“Our mission is to develop and commercialize innovative medicines that change the course of the disease in patients who suffer from age-related brain disorders.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1362% match
“Our mission is to provide drug and product developers with superior scientific research, high-quality research models and innovative analytical instrumentation in order to bring revolutionary new drugs and products to market quickly and safely.”In use 2021 – now·1 sighting·SEC Form S-1, filed 2021-12-2362% match
“Our mission is to design, develop, manufacture and market advanced implantable neuromodulation devices that improve the quality of life for people suffering from chronic intractable pain and other disorders of the nervous system.”In use 2005 – now·1 sighting·SEC Form 10-K, filed 2005-03-1562% match
“Our mission is to bring the unserved rare disease patients the solutions they need through our fully integrated and ongoing clinical development and commercialization expertise.Our core values enable our mission and create a clear pathway forward to meet our strategic goals and objectives.”In use 2024 – now·1 sighting·SEC Form 20-F, filed 2024-04-0462% match
“Our mission is to develop and commercialize therapies with the potential to transform the lives of patients and their families living with rare diseases.”In use 2022 – now·1 sighting·SEC Form 10-K, filed 2022-03-0162% match
“Our mission is to develop novel therapeutics to treat rare, chronic, and serious infectious diseases in areas of high unmet medical need.”In use 2022 – now·1 sighting·SEC Form 424B4, filed 2022-03-2862% match
“Our mission is to develop life-changing genetic medicines for people and their families impacted by devastating neurological diseases.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-2462% match
“Our mission is to discover, develop, and deliver novel, life-transforming therapies to people suffering from rare, severe, and devastating neuromuscular diseases.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0362% match
“Our mission is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs.”In use 2007 – now·1 sighting·SEC Form 10-K, filed 2007-02-2862% match
“The Company’s mission is to improve lives through product innovation, research and development and outstanding patient and consumer experience.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-1362% match
“Our mission is to become the leading company in precision genetic medicines by discovering, developing, manufacturing, and ultimately commercializing a new class of medicines through our proprietary base editing technology, with the goal of providing life-long cures to patients suffering from serious diseases.”In use 2020 – now·1 sighting·SEC Form 424B4, filed 2020-10-0162% match
“Our mission is to improve the lives of patients who suffer from rare diseases for which there are limited or no available treatments, with an initial therapeutic focus on Cirrhosis ascites, patients suffering from AIDS, Cancer and chronic pain, nausea and discomfort associated with chemotherapy and neuropathy.”In use 2017 – now·1 sighting·SEC Form 10-K, filed 2017-11-0662% match
“Our mission is to bring life-changing therapeutics to people living with rare diseases.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-03-1262% match
“Our mission is to become a leading fully-integrated pharmaceutical company delivering new medicines to patients with unmet medical needs.”In use 2016 – now·1 sighting·SEC Form 10-K, filed 2016-03-2862% match
“Our mission is to create long-term stockholder value by acquiring, developing and commercializing innovative products for the treatment of a variety of human diseases that address important unmet medical needs or offer improved, cost-effective alternatives to current methods of treatment.”In use 2014 – now·1 sighting·SEC Form 10-K, filed 2014-03-1162% match
“Our mission is to provide pharmaceutical-grade analysis and testing to the cannabis industry, under ISO-17025:2017 guidelines, to ensure consumers and patients know exactly what is in the cannabis they ingest and to help maximize the quality of our clients’ products through research, development, and standardization.”In use 2024 – now·1 sighting·SEC Form 10-K/A, filed 2024-01-1962% match
“Our mission is to identify, acquire, and accelerate the development and commercialization of medicines that we believe have the potential to offer clinically meaningful, differentiated benefits to patients.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-2861% match
“Our mission is to discover and develop effective biologic treatments applicable to a range of challenging, validated targets with high potential to help people with life-threatening conditions.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1961% match
Showing 1–50 of 50